Influenza virus hemagglutinin mutants

Patent metadata

Field	Value
Publication number	US-12104196-B2
Application number	US-201917255526-A
Country	US
Kind code	B2
Filing date	Jun 27, 2019
Priority date	Jun 27, 2018
Publication date	Oct 1, 2024
Grant date	Oct 1, 2024

Abstract

The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

First claim

The invention claimed is:

1. A modified influenza H3 hemagglutinin (HA) protein comprising an amino acid sequence comprising at least one amino acid substitution when compared to a corresponding wildtype amino acid sequence, said at least one amino acid substitution corresponding to positions 382, 384, 524, and 528 of reference sequence SEQ ID NO: 92, and optionally corresponding to positions 392, 431, 525 and/or 526 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to an alanine or a conserved substitution of alanine,
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to a valine or a conserved substitution of valine,
the amino acid substitution corresponding to position 524 of reference sequence SEQ ID NO: 92 is to a serine or a conserved substitution of serine,
the amino acid substitution corresponding to position 528 of reference sequence SEQ ID NO: 92 is to a leucine or a conserved substitution of leucine,
the amino acid substitution corresponding to position 392 of reference sequence SEQ ID NO: 92 is to an aspartic acid or a conserved substitution of aspartic acid,
the amino acid substitution corresponding to position 431 of reference sequence SEQ ID NO: 92 is to a methionine or a conserved substitution of methionine,
the amino acid substitution corresponding to position 525 of reference sequence SEQ ID NO: 92 is to a leucine or a conserved substitution of leucine, and
the amino acid substitution corresponding to position 526 of reference sequence SEQ ID NO: 92 is to a valine or a conserved substitution of valine.

2. The modified influenza H3 HA of claim 1 , wherein the HA protein further comprises a substitution at amino acids corresponding to positions 525, 526, or 525 and 526 of reference sequence SEQ ID NO: 92.

3. The modified influenza H3 HA of claim 1 , wherein:
the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine;
the conserved substitution of valine is isoleucine, methionine, alanine, or threonine;
the conserved substitution of serine is threonine, alanine, asparagine, aspartic acid, glutamine, glycine, glutamic acid, or lysine; and/or
the conserved substitution of leucine is isoleucine, valine, methionine, phenylalanine, or valine.

4. The modified influenza H3 HA of claim 1 , wherein:
the conserved substitution of aspartic acid is glutamic acid, glutamine, or serine.

5. The modified influenza H3 HA of claim 1 , wherein:
the conserved substitution of methionine is isoleucine, glutamine, valine, or phenylalanine.

6. A nucleic acid encoding the modified influenza H3 HA protein of claim 1 .

7. A virus-like particle (VLP) comprising the modified influenza H3 HA protein of claim 1 .

8. A method of producing an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, comprising:
a) i) introducing the nucleic acid of claim 6 into the plant, portion of the plant, or plant cell, and optionally introducing a second nucleic acid encoding a proton channel protein; or
ii) providing a plant, portion of a plant, or plant cell comprising the nucleic acid of claim 6 , and optionally wherein the plant, portion of the plant, or plant cell further comprises a second nucleic acid encoding a proton channel protein;

b) incubating the plant, portion of the plant, or plant cell under conditions that permit expression of the HA protein encoded by the nucleic acid and optionally the proton channel protein encoded by the second nucleic acid, thereby producing the VLP; and
c) optionally harvesting the plant, portion of the plant, or plant cell, and purifying the VLP.

9. A VLP produced by the method of claim 8 , optionally further comprising one or more than one lipid derived from the plant, portion of the plant, or plant cell, plant-specific N-glycans, modified N-glycans or a combination thereof.

10. A plant, portion of the plant, or plant cell comprising the VLP of claim 7 .

11. A composition for inducing an immune response comprising, an effective dose of the VLP of claim 7 , and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient.

12. The VLP of claim 7 , for use in inducing immunity to an influenza infection in a subject, wherein the VLP is optionally administered to the subject orally, intranasally, intramuscularly, intraperitoneally, intravenously or subcutaneously.

13. A method of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, comprising:
a) introducing the nucleic acid of claim 6 into the plant, portion of the plant, or plant cell; or providing a plant, portion of a plant, or plant cell comprising the nucleic acid of claim 6 ;
b) incubating the plant, portion of the plant, or plant cell under conditions that permit expression of the modified influenza HA protein encoded by the nucleic acid, thereby producing the VLP at a higher yield compared to plant, portion of the plant, or plant cell expressing an unmodified influenza HA protein; and
c) optionally harvesting the plant, portion of the plant, or plant cell, and purifying the VLP.

14. The method of claim 8 , wherein the proton channel protein is an influenza A subtype M2 protein.

15. A modified influenza H3 hemagglutinin (HA) protein comprising amino acid substitutions corresponding to positions 382, 384, 524, and 528 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 is to alanine or a conserved substitution of alanine,
the amino substitution corresponding to position 384 is to valine or a conserved substitution of valine;
the amino acid substitutions corresponding to position 524 is to serine or a conserved substitution of serine; and
the amino acid substitutions corresponding to position 528 is to leucine or a conserved substitution of leucine.

Assignees

• Medicago Inc
• Aramis Biotechnologies Inc

Inventors

• Lavoie Pierre-Olivier
• Lorin Aurelien
• Doucet Alain
• D'Aoust Marc-Andre
• Couture Manon

Classifications

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C12N2760/16033

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• C12N2760/16023

  Virus like particles [VLP] · CPC title

• C12N15/8257

  for the production of primary gene products, e.g. pharmaceutical products, interferon · CPC title

• C07K16/10

  RNA viruses · CPC title